integrated biopharma inc is a pharmaceuticals company based out of 225 long avenue, hillside, new jersey, united states.
Company profile
Ticker
INBP
Exchange
Website
CEO
Riva Kay Sheppard / Christina Kay
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CHEM INTERNATIONAL INC, INTEGRATED HEALTH TECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
Manhattan Drug Company, Inc. • AgroLabs, Inc. • IHT Health Products, Inc. • Vitamin Factory, Inc. • IHT Properties, Inc. • MDC Warehousing and Distribution, Inc. • InB:Paxis Pharmaceuticals, Inc. ...
IRS number
222407475
INBP stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
12 Feb 24
10-Q
2024 Q2
Quarterly report
12 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
27 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
10-Q
2024 Q1
Quarterly report
9 Nov 23
DEF 14A
Definitive proxy
27 Oct 23
8-K
Results of Operations and Financial Condition
15 Sep 23
10-K
2023 FY
Annual report
15 Sep 23
8-K
Results of Operations and Financial Condition
11 May 23
10-Q
2023 Q3
Quarterly report
11 May 23
Latest ownership filings
4
SHEPPARD RIVA
29 Nov 23
4
CHRISTINA KAY
29 Nov 23
4
Dina Masi
29 Nov 23
SC 13D
INTEGRATED BIOPHARMA / INTEGRATED BIOPHARMA ownership change
16 Nov 23
5
E GERALD KAY
16 Nov 23
3
Gerald Kay Estate Edward
16 Nov 23
SC 13D
INTEGRATED BIOPHARMA / INTEGRATED BIOPHARMA ownership change
14 Nov 23
4
SHEPPARD RIVA
21 Sep 23
4
CHRISTINA KAY
21 Sep 23
4
Dina Masi
21 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.59 mm | 2.59 mm | 2.59 mm | 2.59 mm | 2.59 mm | 2.59 mm |
Cash burn (monthly) | (no burn) | (no burn) | 18.00 k | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 119.45 k | n/a | n/a | n/a |
Cash remaining | n/a | n/a | 2.47 mm | n/a | n/a | n/a |
Runway (months of cash) | n/a | n/a | 137.5 | n/a | n/a | n/a |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Nov 23 | Dina Masi | Stock Option Common Stock | Grant | Acquire A | No | No | 0.24 | 150,000 | 36.00 k | 150,000 |
28 Nov 23 | Christina Kay | Stock Option Common Stock | Grant | Acquire A | No | No | 0.26 | 150,000 | 39.00 k | 150,000 |
28 Nov 23 | Sheppard Riva | Stock Option Common Stock | Grant | Acquire A | No | No | 0.26 | 150,000 | 39.00 k | 150,000 |
20 Sep 23 | Dina Masi | Common Stock | Grant | Acquire A | No | No | 0.09 | 50,000 | 4.50 k | 147,200 |
20 Sep 23 | Dina Masi | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.09 | 50,000 | 4.50 k | 576,667 |
18 Jul 23 | Robert Canarick | Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 50,000 |